NOXXON Pharma AG
Edit

NOXXON Pharma AG

http://www.noxxon.com/
Last activity: 31.01.2022
Active
Categories: AlternativeBioTechBuildingCareDataDevelopmentManagementMedtechPlatform
NOXXON Pharma is a clinical-stage biopharmaceutical company whose core focus is on improving cancer treatment by targeting the tumor microenvironment. NOXXON’s goal is to significantly enhance the effectiveness of cancer treatments including immuno-oncology approaches (such as immune checkpoint inhibitors) and current standards of care (such as chemotherapy and radiotherapy).

NOXXON's Spiegelmer® platform has generated a proprietary pipeline of clinical-stage assets including its lead cancer candidate NOX-A12, which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to study NOX-A12 combined with KEYTRUDA® (pembrolizumab) in pancreatic and colorectal cancer. NOXXON’s pipeline also contains NOX-E36, which targets other tumor microenvironment targets implicated in cancer spread and immune privilege of tumors.
Mentions
37
Total raised: $66.34M
Founded date: 1998
Twitter
LinkedIn

Investors 4

Funding Rounds 6

DateSeriesAmountInvestors
29.12.2021-$19.18M-
30.04.2021-$1.45M-
06.08.2019-$1.12M-
09.05.2017-$1.09M-
12.10.2010Series D$2.78M-
27.05.2010-$40.72M-

Mentions in press and media 37

DateTitleDescription
31.01.2022NOXXON ANNOUNCES EUR2.375 MILLION FINANCING UNDER AGREEMENT WITH ATLASBerlin, Germany - NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced that it has drawn down additional financing tranche...
29.12.2021NOXXON Pharma N : secures Euro 17 million expansion of equity-linked facility with Atlas to advance NOX-A12 in glioblastoma and pancreatic cancer programsNOXXON SECURES €17 MILLION EXPANSION OF EQUITY-LINKED FACILITY WITH ATLAS TO ADVANCE NOX-A12 IN GLIOBLASTOMA AND PANCREATIC CANCER PROGRAMS Substantial extension of financial runway visibility into December 2022 Financing availability secur...
15.12.2021NOXXON Pharma N : announces results of the extraordinary general meeting of shareholdersNOXXON ANNOUNCES RESULTS OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Berlin, Germany, December 15, 2021, 06:00 p.m. CET - NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatm...
15.12.2021NOXXON Pharma N : to participate in banking and investor conferences in January and February 2022NOXXON TO PARTICIPATE IN BANKING AND INVESTOR CONFERENCES IN JANUARY AND FEBRUARY 2022 Berlin, Germany, December 15, 2021, 08:00 a.m. CET - NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving canc...
22.11.2021NOXXON: New Phase 1/2 data on NOX-A12 & radiotherapy combination in brain cancer presented at the Society for Neuro-Oncology Annual Meeting 2021NOXXON: NEW PHASE 1/2 DATA ON NOX-A12 & RADIOTHERAPY COMBINATION IN BRAIN CANCER PRESENTED AT THE SOCIETY FOR NEURO- ONCOLOGY ANNUAL MEETING 2021 New data from GLORIA Phase 1/2 study show impact of CXCL12 inhibition on tumor blood vesse...
15.11.2021NOXXON Pharma N : announces convocation of an Extraordinary General Meeting of shareholdersNOXXON ANNOUNCES CONVOCATION OF AN EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Appointment of Bryan Jennings to the Board of Directors through the binding nomination of the Supervisory Board Berlin, Germany, November 15, 2021, 08.00 a.m. ...
09.11.2021NOXXON to present at the third edition of Investir Day on November 23 in Paris, FranceNOXXON TO PRESENT AT THE THIRD EDITION OF INVESTIR DAY ON NOVEMBER 23 IN PARIS, FRANCE Berlin, Germany, November 9, 2021, 08:00 a.m. CET - NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cance...
03.11.2021NOXXON provides update on timing for upcoming trials of NOX-A12 in pancreatic and brain cancerNOXXON PROVIDES UPDATE ON TIMING FOR UPCOMING TRIALS OF NOX-A12 IN PANCREATIC AND BRAIN CANCER Berlin, Germany, November 3, 2021, 08:00 a.m. CET - NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improvi...
27.10.2021Experienced financial executive, Bryan Jennings, joins NOXXON as CFOEXPERIENCED FINANCIAL EXECUTIVE, BRYAN JENNINGS, JOINS NOXXON AS CFO Berlin, Germany, October 27, 2021, 08:00 a.m. CEST - NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by t...
19.10.2021NOXXON Pharma N : announces planned expansion of Phase 1/2 NOX-A12 brain cancer trialNOXXON ANNOUNCES PLANNED EXPANSION OF PHASE 1/2 NOX-A12 BRAIN CANCER TRIAL Berlin, Germany, October 19, 2021, 08:00 a.m. CEST - NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatment...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In